Pharmaceutical Supply and Dosing Strategy Support

The contract pertains to the formulation, stability testing, and supply chain management of ibogaine or closely related compounds under an Investigational New Drug application to support clinical research initiatives. It requires the secure and compliant production of precise dosing formulations, adherence to rigorous pharmaceutical standards for compound stability, and robust logistics to ensure uninterrupted delivery of materials to authorized research sites. All activities must align with federal regulatory requirements governing investigational substances and be executed within a tightly controlled framework to maintain quality, safety, and chain-of-custody integrity throughout the supply lifecycle. The work is being solicited as a subcontract under the Advanced Research Projects Agency for Health, a division of the Department of Health and Human Services, with a primary focus on accelerating innovative therapeutic development. The solicitation is open for responses until October 15, 2026, and the North American Industry Classification System code 325412 indicates the scope involves pharmaceutical preparations manufacturing. Performance is expected to meet stringent federal standards for investigational drug supply, with no geographical restrictions specified on place of performance, allowing for flexible, secure, and scalable logistical execution across approved facilities.